Urologic Oncology: Seminars and Original Investigations
Seminars articleCancer immunotherapy: A paradigm shift in the treatment of advanced urologic cancers
References (7)
- et al.
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Lancet Oncol
(2014) - et al.
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Lancet
(2017) - et al.
IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance
Trends Immunol
(2016)
Cited by (11)
Combined chemotherapy and radiotherapy improves survival in 1897 testicular Lymphoma patients from a contemporary cohort
2020, Urologic Oncology: Seminars and Original InvestigationsCitation Excerpt :The NCDB, a clinical oncology database jointly sponsored by the American College of Surgeons and the American Cancer Society, was used for these analyses. NCDB is sourced from hospital registry data collected from more than 1,500 Commission-on-Cancer accredited facilities and includes data on over 70% of all malignancies diagnosed in the United States [10]. Our Institutional Review Board waived approval for this study because NCDB patient and facility data is deidentified.
Angiogenic and immunological pathways in metastatic renal cell carcinoma: A counteracting paradigm or two faces of the same medal? The GIANUS Review
2019, Critical Reviews in Oncology/HematologyCitation Excerpt :Over the last decade, in the so-called “antiangiogenic era”, a number of targeted therapies have been approved for the treatment of metastatic renal cell carcinoma (mRCC) (Choueiri and Motzer, 2017; Vitale and Carteni, 2016). More recently, immunotherapy has undergone a resurgence in clinical practice (Gill and Agarwal, 2017). In 2016 the European Society for Medical Oncology (ESMO) guideline still recommended bevacizumab plus interferon (IFN)-α, sunitinib or pazopanib as first-line treatment in patients with good or intermediate risk and clear-cell histology and temsirolimus for the poor risk cases (Escudier et al., 2016).
Number of FoxP3+ regulatory T-cells are associated with recurrence in vulvar squamous cell carcinoma
2023, Journal of Gynecologic OncologyMetastatic Renal Cell Carcinoma Presenting as a Rapidly Enlarging Endotracheal Mass Due to Hyperprogression on Anti-PD1 Immunotherapy
2021, Ear, Nose and Throat Journal